Sellas Life Sciences is trading at $11.98, up 4.04%, rebounding after September 23’s decline; no clear catalyst for today’s gain was identified. - Shares fell 4.16% on September 23; no new company-specific announcement was identified for September 24. - September 22 coverage focused on a Pomerantz investor investigation related to delayed REGAL trial disclosure, but it does not clearly explain the gain. - Biotech-sector weakness and nearly flat major indexes offer no strong direct catalyst.